Novel Novartis Drug LCZ696 Shows Promise in Cutting Cardiovascular Deaths
A novel drug produced by Swiss multinational pharmaceutical company Novartis could prove to be a radical treatment for patients with heart failure. The experimental medicine, currently classified as LCZ696, was found to cut the risk of cardiovascular deaths ...
Read Full Story
Advertise Here contact ads[@]ghheadlines.com
Facebook
Twitter
Pinterest
Instagram
Google+
YouTube
LinkedIn
RSS